gliclazide has been researched along with Body Weight in 30 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several observational studies were conducted with vildagliptin in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan, showing significantly lower incidences of hypoglycemia with vildagliptin versus sulfonylureas, including gliclazide." | 5.19 | A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. ( Abdallah, K; Hassanein, M; Schweizer, A, 2014) |
| "Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change, incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with other oral blood glucose lowering drugs." | 4.90 | Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. ( Bilo, HJ; de Bock, GH; Gans, RO; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; van Dijk, PR; van Hateren, KJ, 2014) |
| "The body weight increased after the treatment in the normal group,blank group,and gliclazide group [(241." | 3.81 | [Alisma versus Gliclazide in the Treatment of Primary Diabetes in Goto-Kakizaki Rats]. ( Ding, CY; Shi, NC; Tan, QY, 2015) |
| "The combined treatment of deprenyl and gliclazide may contribute to the control of the physiopathological mechanisms underlying both the process of aging and type 2 diabetes by reducing oxidant stress and DNA damage, improving antioxidant status, and increasing survival, and may have implications for further clinical studies." | 3.73 | Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model. ( Alper, G; Caglayan, O; Duman, E; Irer, S; Yilmaz, C, 2005) |
| "The clinical efficacy of gliclazide and its effect on plasma glucose, body weight and serum lipids was assessed in a 3 months open trial of 30 obese, Non-Insulin Dependent diabetes mellitus (NIDDM) patients who failed to respond to diet therapy alone." | 3.68 | Gliclazide in the treatment of obese non-insulin dependent diabetic patients. ( Seshiah, V; Suresh, K; Venkataraman, S, 1993) |
| "A long-term follow-up study was carried out in 44 Type II diabetic patients to confirm the lack of effect of gliclazide on body weight as well as its hypoglycaemic efficacy and tolerance." | 3.67 | Lack of weight gain with gliclazide treatment for 30 months in type II diabetes. ( Lowe, SM; Robb, GH, 1984) |
| "3% of ideal body weight), with an impaired daily glycaemic profile despite a carbohydrate restrictive diet were treated with gliclazide (40 to 320 mg per day) for 36 months." | 3.67 | Is sulphonylurea therapy effective long term? A 3-year study with gliclazide. ( Lavielle, R; Zurro Hernandez, J, 1986) |
| "Gliclazide is an oral hypoglycaemic agent which has been shown in animal models to reduce platelet adhesiveness." | 2.64 | Effect on platelet adhesiveness in diabetics after long-term treatment with a new oral hypoglycaemic agent, gliclazide. ( Coce, F; Maitre, D; Mustovic, D; Rubinjoni, Z; Skrabalo, Z; Turk, Z, 1978) |
| "Ulcerative Colitis is a universal autoimmune disease with high incidence rates worldwide." | 1.56 | Gliclazide attenuates acetic acid-induced colitis via the modulation of PPARγ, NF-κB and MAPK signaling pathways. ( Arafa, EA; Mohamed, WR; Omar, HA; Zaher, DM, 2020) |
| "To analyze the efficacy and safety of replacing sitagliptin with canagliflozin in patients with type 2 diabetes (T2D) and poor metabolic control despite treatment with sitagliptin in combination with metformin and/or gliclazide." | 1.48 | Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. ( Garcia de Lucas, MD; Gómez Huelgas, R; Olalla Sierra, J; Pérez Belmonte, LM; Suárez Tembra, M, 2018) |
| "Gliclazide and HP were administered daily via gavage for 8 weeks." | 1.46 | Renoprotective effect of Hypericum perforatum against diabetic nephropathy in rats: Insights in the underlying mechanisms. ( Abd El Aleem, DI; Abd El Motteleb, DM, 2017) |
| "Approximately 40% of patients with type 2 diabetes may progress to nephropathy and a good metabolic control can prevent the development of diabetic renal injury." | 1.37 | Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. ( da Cunha, FX; Louro, TM; Matafome, PN; Nunes, EC; Seiça, RM, 2011) |
| "The study objective was to determine if Ramadan fasting was safe in patients with type 2 diabetes mellitus (T2D), based upon a determination of the effect of fasting on a broad range of physiological and clinical parameters, including markers of glycemic control and blood pressure." | 1.35 | Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control? ( Chabraoui, L; Chebraoui, L; Chraibi, A; El Guessabi, L; Fellat, S; Israili, ZH; Lyoussi, B; M'guil, M; Ragala, MA, 2008) |
| "Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring." | 1.35 | Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. ( Louro, T; Matafome, P; Monteiro, P; Nunes, E; Seiça, R; Sena, CM, 2009) |
| "Mean body weight was reduced, particularly in obese and elderly subjects and those treated previously with sulphonylurea drugs." | 1.27 | Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial. ( Campbell, DB; Shaw, KM; Ward, JD; Wheeley, MS, 1985) |
| "Gliclazide is a suitable oral hypoglycaemic agent for use in the obese diabetic who cannot be controlled by diet alone." | 1.27 | A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes. ( Frier, BM; Kay, JW; McAlpine, CH; McAlpine, LG; Storer, AM; Waclawski, ER, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (26.67) | 18.7374 |
| 1990's | 6 (20.00) | 18.2507 |
| 2000's | 8 (26.67) | 29.6817 |
| 2010's | 7 (23.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Arafa, EA | 1 |
| Mohamed, WR | 1 |
| Zaher, DM | 1 |
| Omar, HA | 1 |
| Fadini, GP | 1 |
| Zatti, G | 1 |
| Baldi, I | 1 |
| Bottigliengo, D | 1 |
| Consoli, A | 1 |
| Giaccari, A | 1 |
| Sesti, G | 1 |
| Avogaro, A | 1 |
| Garcia de Lucas, MD | 1 |
| Pérez Belmonte, LM | 1 |
| Suárez Tembra, M | 1 |
| Olalla Sierra, J | 1 |
| Gómez Huelgas, R | 1 |
| Landman, GW | 1 |
| de Bock, GH | 1 |
| van Hateren, KJ | 1 |
| van Dijk, PR | 1 |
| Groenier, KH | 1 |
| Gans, RO | 1 |
| Houweling, ST | 1 |
| Bilo, HJ | 1 |
| Kleefstra, N | 1 |
| Hassanein, M | 1 |
| Abdallah, K | 1 |
| Schweizer, A | 1 |
| Ding, CY | 1 |
| Tan, QY | 1 |
| Shi, NC | 1 |
| Abd El Motteleb, DM | 1 |
| Abd El Aleem, DI | 1 |
| M'guil, M | 1 |
| Ragala, MA | 1 |
| El Guessabi, L | 1 |
| Fellat, S | 1 |
| Chraibi, A | 1 |
| Chabraoui, L | 1 |
| Chebraoui, L | 1 |
| Israili, ZH | 1 |
| Lyoussi, B | 1 |
| Sivakumar, S | 1 |
| Subramanian, SP | 1 |
| Louro, TM | 1 |
| Matafome, PN | 1 |
| Nunes, EC | 1 |
| da Cunha, FX | 1 |
| Seiça, RM | 1 |
| Juang, JH | 1 |
| Kuo, CH | 1 |
| Hsu, BR | 1 |
| Tan, MH | 1 |
| Baksi, A | 1 |
| Krahulec, B | 1 |
| Kubalski, P | 1 |
| Stankiewicz, A | 1 |
| Urquhart, R | 3 |
| Edwards, G | 2 |
| Johns, D | 2 |
| Charbonnel, B | 1 |
| Roden, M | 1 |
| Mariz, S | 1 |
| Mihm, M | 1 |
| Widel, M | 1 |
| Tan, M | 1 |
| Belcher, G | 1 |
| Lambert, C | 1 |
| Matthews, DR | 1 |
| Alper, G | 1 |
| Irer, S | 1 |
| Duman, E | 1 |
| Caglayan, O | 1 |
| Yilmaz, C | 1 |
| Sena, CM | 1 |
| Louro, T | 1 |
| Matafome, P | 1 |
| Nunes, E | 1 |
| Monteiro, P | 1 |
| Seiça, R | 1 |
| Robb, GH | 1 |
| Lowe, SM | 1 |
| Wajchenberg, BL | 1 |
| Nery, M | 1 |
| Leme, CE | 1 |
| Silveira, AA | 1 |
| Fioratti, P | 1 |
| Germek, OA | 1 |
| Seshiah, V | 1 |
| Venkataraman, S | 1 |
| Suresh, K | 1 |
| Page, RC | 1 |
| Harnden, KE | 1 |
| Walravens, NK | 1 |
| Onslow, C | 1 |
| Sutton, P | 1 |
| Levy, JC | 1 |
| Hockaday, DT | 1 |
| Turner, RC | 1 |
| Qiang, X | 1 |
| Satoh, J | 1 |
| Sagara, M | 1 |
| Fukuzawa, M | 1 |
| Masuda, T | 1 |
| Miyaguchi, S | 1 |
| Takahashi, K | 1 |
| Toyota, T | 1 |
| Estivals, JP | 1 |
| Giraudet, MC | 1 |
| Videau, JY | 1 |
| Rubinjoni, Z | 1 |
| Turk, Z | 1 |
| Coce, F | 1 |
| Mustovic, D | 1 |
| Maitre, D | 1 |
| Skrabalo, Z | 1 |
| Bernasconi, D | 1 |
| Mazzi, C | 1 |
| Kawai, K | 1 |
| Suzuki, S | 1 |
| Murayama, Y | 1 |
| Watanabe, Y | 1 |
| Yamashita, K | 1 |
| Noury, J | 1 |
| Nandeuil, A | 1 |
| Katsumata, K | 1 |
| Katsumata, Y | 1 |
| Shaw, KM | 1 |
| Wheeley, MS | 1 |
| Campbell, DB | 1 |
| Ward, JD | 1 |
| McAlpine, LG | 1 |
| McAlpine, CH | 1 |
| Waclawski, ER | 1 |
| Storer, AM | 1 |
| Kay, JW | 1 |
| Frier, BM | 1 |
| Zurro Hernandez, J | 1 |
| Lavielle, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan[NCT01758380] | Phase 4 | 557 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes[NCT01156597] | Phase 3 | 30 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The ability of serum HDL to remove cholesterol from cultured cells will be assessed as an in vitro method to evaluate a functional changes in HDL mediated by changes due to pioglitazone treatment. Cells were incubated with 2% serum from each study subject diluted in culture medium and incubations were performed for a total of 4 hours. Cholesterol efflux was calculated as the percent of cholesterol removed from the cells and appearing in the culture medium normalized to a reference serum pool as described in detail by de la Llera-Moya et al (de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158. PMID: 20075420). (NCT01156597)
Timeframe: 24 weeks
| Intervention | Ratio (Mean) |
|---|---|
| Pioglitazone Group | 1.02 |
| Comparator Group | 1.05 |
Lipoproteins will be isolated and analyzed using the gradient ultracentrifugation-high pressure liquid chromatography technique to isolate very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), LDL, and high density lipoprotein (HDL) subfractions. Protein and lipid compositions of HDL is determined (NCT01156597)
Timeframe: 24 weeks
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| HDL-apoAI at end point | HDL-apoAII at end point | HDL-apoCI at end point | HDL-apoCII at end point | HDL-apoCIII at end point | HDL-apoM at end point | |
| Comparator Group | 65.7 | 22.6 | 8.4 | 2.8 | 12.5 | 0.43 |
| Pioglitazone Group | 65.0 | 26.6 | 10.9 | 3.5 | 11.8 | 0.62 |
"The primary endpoint will be increased high density lipoprotein cholesterol and decreased triglycerides measured as the difference after 12 or 24 weeks of treatment from baseline levels. The data are expressed as the percent change from the baseline value and calculated using he equation:~Change=[100%*(Endpoint value - Baseline Value)/Baseline Value]" (NCT01156597)
Timeframe: 24 weeks
| Intervention | % Change (Mean) | |||
|---|---|---|---|---|
| % Change in HDL cholesterol at 12 weeks | % Change in HDL cholesterol at 24 weeks | % Change in triglycerides at 12 weeks | % Change in triglycerides at 24 weeks | |
| Comparator Group | 2.7 | -1.5 | 7.4 | 19.7 |
| Pioglitazone Group | 7.9 | 15.7 | -10.9 | -15.4 |
2 reviews available for gliclazide and Body Weight
| Article | Year |
|---|---|
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
Topics: Administration, Oral; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2014 |
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Me | 2005 |
8 trials available for gliclazide and Body Weight
| Article | Year |
|---|---|
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Topics: Adamantane; Asia; Biomarkers; Blood Glucose; Body Weight; Counseling; Diabetes Mellitus, Type 2; Dip | 2014 |
Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glyc | 2005 |
Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Me | 2005 |
Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; | 2005 |
'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance.
Topics: Adolescent; Adult; Body Weight; Cardiovascular Diseases; Double-Blind Method; Exercise Therapy; Glic | 1993 |
[Survey of 832 case records of diabetes of adult onset treated by Diamicron. Evolution of metabolism and weight].
Topics: Adult; Aged; Biguanides; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Fe | 1978 |
Effect on platelet adhesiveness in diabetics after long-term treatment with a new oral hypoglycaemic agent, gliclazide.
Topics: Adult; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diet, Diabetic; Fema | 1978 |
Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Gliclazide; Hum | 1991 |
21 other studies available for gliclazide and Body Weight
| Article | Year |
|---|---|
Gliclazide attenuates acetic acid-induced colitis via the modulation of PPARγ, NF-κB and MAPK signaling pathways.
Topics: Acetic Acid; Animals; Apoptosis; Body Weight; Caspase 3; Caspase Inhibitors; Colitis, Ulcerative; Co | 2020 |
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; D | 2018 |
Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; | 2018 |
[Alisma versus Gliclazide in the Treatment of Primary Diabetes in Goto-Kakizaki Rats].
Topics: Alisma; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Gliclazide; Rats; Rats | 2015 |
Renoprotective effect of Hypericum perforatum against diabetic nephropathy in rats: Insights in the underlying mechanisms.
Topics: Animals; Antioxidants; Apoptosis; Body Weight; Collagen Type IV; Cyclooxygenase 2; Cytoprotection; D | 2017 |
Is Ramadan fasting safe in type 2 diabetic patients in view of the lack of significant effect of fasting on clinical and biochemical parameters, blood pressure, and glycemic control?
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; C-Peptide; Cholesterol, HDL; Diabetes M | 2008 |
D-pinitol attenuates the impaired activities of hepatic key enzymes in carbohydrate metabolism of streptozotocin-induced diabetic rats.
Topics: Animals; Body Weight; Carbohydrate Metabolism; Diabetes Mellitus, Experimental; Gliclazide; Glucose | 2009 |
Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2011 |
Effect of gliclazide on islet transplants.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Gliclazide; Hypoglycemic Agent | 2002 |
Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aging; Animals; Antioxidants; Blood Glucose; Body Weight; Deoxyguanosin | 2005 |
Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcholine; Animals; Antioxidants; Body Weight; Deoxyguanosine; Diab | 2009 |
Lack of weight gain with gliclazide treatment for 30 months in type II diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Male | 1984 |
Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus; Gliclazide; Humans; Hypoglycemic Agents; Insuli | 1980 |
Gliclazide in the treatment of obese non-insulin dependent diabetic patients.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans | 1993 |
Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Gliclaz | 1998 |
[Therapeutic value of a new oral antidiabetic agent: gliclazide].
Topics: Adult; Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus; Drug Evaluation; Drug | 1978 |
Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mel | 1991 |
The potentiating effect of the simultaneous administration of tolbutamide, glibenclamide, and gliclazide on the development of alloxan-induced diabetes in rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Synergism; Gliclazide; Gl | 1990 |
Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypoglycemic Agents; Moni | 1985 |
A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Insu | 1988 |
Is sulphonylurea therapy effective long term? A 3-year study with gliclazide.
Topics: Analysis of Variance; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dietary Carbohydrates; | 1986 |